Research programme: hyperlipidaemia therapeutics - SunTen Phytotech
Alternative Names: STD 052Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator SunTen Phytotech
- Developer Lumosa Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in Taiwan
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Taiwan
- 19 May 2008 This programme is still in active development